Monica Elise Johnson, DPT | |
6208 Montrose Rd, Rockville, MD 20852 | |
(301) 468-9343 | |
Not Available |
Full Name | Monica Elise Johnson |
---|---|
Gender | Female |
Speciality | Physical Therapist |
Location | 6208 Montrose Rd, Rockville, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1407939093 | NPI | - | NPPES |
409567700 | Medicaid | MD |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2081P0010X | Physical Medicine & Rehabilitation - Pediatric Rehabilitation Medicine | 21543 (Maryland) | Secondary |
225100000X | Physical Therapist | 21543 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Monica Elise Johnson, DPT 6208 Montrose Rd., Rockville, MD 20852-4348 Ph: (301) 468-9343 | Monica Elise Johnson, DPT 6208 Montrose Rd, Rockville, MD 20852 Ph: (301) 468-9343 |
News Archive
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has received Investigational Device Exemption (IDE) conditional approval from the United States Food and Drug Administration ("FDA") to begin a prospective, multicenter, randomized clinical trial for a bilateral percutaneous approach to endovascular abdominal aortic aneurysm repair (EVAR) utilizing the Company's IntuiTrak(TM) endovascular delivery system for the Powerlink® family of stent grafts.
"The world is facing two immediate health crises concerning drugs and vaccines: affordable and reliable access to life-sparing medicines and the safety and reliability of those medicines," Laurie Garrett, senior fellow for global health at the Council on Foreign Relations (CFR), writes in the council's Policy Innovation Memorandum No. 21, titled, "Ensuring the Safety and Integrity of the World's Drug, Vaccine, and Medicines Supply."
The World Food Programme (WFP) "is helping feed more than 10 million people in eight countries" in the Sahel, but WFP Executive Director Ertharin Cousin "stressed the crisis was not over," AlertNet reports.
Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen.
› Verified 7 days ago